4D pharma plc (LON:DDDD – Get Rating)'s share price traded up 5% on Tuesday . The stock traded as high as GBX 16.86 ($0.20) and last traded at GBX 16.66 ($0.20). 912,370 shares were traded during mid-day trading, a decline of 69% from the average session volume of 2,957,490 shares. The stock had previously closed at GBX 15.86 ($0.19).
4D pharma Stock Performance
The company has a debt-to-equity ratio of 39.50, a current ratio of 5.21 and a quick ratio of 4.72. The firm has a market cap of £30.04 million and a price-to-earnings ratio of -1.08. The company has a fifty day moving average price of GBX 16.66 and a two-hundred day moving average price of GBX 27.35.
4D pharma Company Profile
(Get Rating)
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.
Featured Articles
- 3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
- Don't Forget About These Cheap, Fundamentally Strong Tech Stocks
- Bellwether RPM International Pops On Results
- Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
- Hot Potato: Lamb Weston Stock Confirms a Top
Receive News & Ratings for 4D pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D pharma and related companies with MarketBeat.com's FREE daily email newsletter.
